Current Research in Triple-Negative Breast Cancer
Richard S. Finn, MD, discusses current research in triple-negative breast cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).
Clinical Pearls:
- TNBC is an area of unmet need and is defined by the absence of a druggable target
- Researchers have studied Src inhibition and PARP inhibition in this space
- A new PARP inhibitor, BMN 673, looks particularly potent forBRCA-mutated breast cancer
- Patients withBRCA-mutated breast cancer are often triple negative
- There is still a need to better understand the biology of TNBC in order to bring the right drugs to these patients
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
